Printer Friendly

Advanced Tissue Sciences, MIT and Children's Hospital of Boston announce new tissue engineering patents

Advanced Tissue Sciences, Inc. (La Jolla, CA; 619-450-5802), the Massachusetts Institute of Technology (Cambridge, MA; 617-258-5402)and Children's Hospital (Boston, MA; 617-355-8834), announced the issuance of three United States patents covering the growth of vascularized human tissues or organs on three-dimensional biocompatible, biodegradable and nonbiodegradable polymer scaffolds inside the body (in vivo). Advanced Tissue Sciences has license rights to these patents with respect to a broad range of tissues and organs. These patents complement Advanced Tissue Sciences' core patents covering the growth of tissues outside the body (ex vivo) and expand its opportunity to develop tissue engineered products. Research using this technology on a wide variety of tissues and organs has been described in more than 400 scientific publications and presentations over the last eight years. Under the technology described in the three patents (United States Patents 5,759,830; 5,770,193; 5,770,417), vascularized tissues are grown by first seeding cells on a scaffold and then implanting the cell-scaffold in the patient at the site in need of tissue repair or replacement. Over time, the cells grow into a fully functional tissue using the body as the incubator. "Tissue engineering, the science of creating new tissues and organs for transplantation, has already successfully produced products which are helping patients worldwide. The combination of our original patents and these newly issued patents provide us the technology platform to grow tissues both inside and outside the body," said Gail K. Naughton, PhD, president and chief operating officer of Advanced Tissue Sciences. "These patents provide us with the opportunity to develop tissue engineered products in a way that benefits the patient and can be cost effective." Advanced Tissue Sciences is a tissue engineering company utilizing its proprietary core technology to develop and manufacture human tissue products for tissue repair and transplantation. The company currently has two products in the market, Dermagraft, a living, permanent dermal replacement for the treatment of diabetic foot ulcers (currently available in Canada and the UK), and Dermagraft-TC, a temporary covering for full and partial-thickness burns. In addition to Dermagraft and Dermagraft-TC, the company also is developing products for cartilage and cardiovascular applications. The Massachusetts Institute of Technology is one of the world's outstanding universities. In 1997-98 it has 9,880 students from all 50 states, the District of Columbia, three territories and 108 foreign countries. Eleven members of the MIT faculty and an MIT physician are Nobel laureates. MIT routinely leads all United States universities in patents granted and signs about 70 license agreements with private companies each year. Children's Hospital of Boston, is the nation's leading pediatric medical center offering a complete range of health services for patients from birth through age twenty-one and is the primary pediatric teaching hospital of Harvard Medical School (Cambridge, MA), the world's premier pediatric research facility. Representative samples of peer reviewed publications describing the technology covered by these patents include: Uyama S, Kaufmann P, Takeda T, Vacanti JP: Delivery of whole liver- equivalent hepatocyte mass using polymer devices and hepatotrophic stimulation. Transplantation 1993; 55: 932. Organ GM, Mooney DJ, Hansen LK, Schloo B, Vacanti JP: Design and transplantation of enterocyte-polymer constructs: A small animal model for neointestinal replacement in short bowel syndrome. American College of Surgeons 1993 Surgical Forum Volume XLIV. Mooney DJ, Breuer C, McNamara K, Vacanti JP, Langer R: Fabricating tubular devices from polymers of lactic glycolic acid for tissue engineering. Tissue Engineering 1995; 1: 107. Vacanti CA, Kim W, Upton J, Vacanti MP, Mooney D, Schloo B, Vacanti JP: Tissue engineered growth of bone and cartilage. Transplantation Proceedings 1993; 25: 1019. Cao Y, Vacanti JP, Ma X, Paige KT, Upton J, Chowanski Z, Schloo B, Langer R, Vacanti CA: The generation of neo-tendon using synthetic polymers seeded with tenocytes. Abstract.
COPYRIGHT 1998 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Patent granted for growing various artificial body parts
Publication:BIOTECH Patent News
Article Type:Article
Geographic Code:1USA
Date:Jun 1, 1998
Words:625
Previous Article:Case Western Reserve University applies for patent
Next Article:Human Pheromone Sciences settles patent infringement lawsuit
Topics:


Related Articles
Tissue engineering: replacing damaged organs with new tissues.
Advanced Tissue Sciences reports on physiological properties of living vascular grafts.
Advanced Tissue Sciences receives patent for growing living cartilage with mesenchymal stem cells.
Thm Biomedical receives patent for a method and device for the reconstruction of articular cartilage.
Reprogenesis acquires exclusive license to Children's Hospital/Harvard/MIT organ regeneration technology and product for bladder reconstruction.
Advanced Tissue Sciences receives broad bioreactor patent.
ORTEC SUCCESSFULY DEFENDS EUROPEAN PATENT ON ORCEL.
DENTIGENIX OPTIONS REGENERATED-TOOTH TECHNOLOGY.
GMP obtains two patents involving bag proteins and nucleic acid molecules encoding them and porous biodegradable polymeric materials for cell...
CRYO-CELL signs exclusive license to market new stem cell service.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters